Bispecific anti-CD3 ×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies

In conclusion, CD155Bi-Ab enhances the ability of T cells to kill haematologic tumour cells, and therefore, CD155 may serve as a novel target for immunotherapy against haematologic malignancies.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research